



## **SQI Diagnostics Inc.**

**Condensed Interim Consolidated Financial Statements**

**(Unaudited)**

**(Expressed in Canadian dollars)**

**For the Three and Nine Months Ended June 30, 2021, and 2020.**

### **Notice to Reader**

**The accompanying unaudited financial statements have been prepared by management and the Company's independent auditors have not performed a review of these financial statements.**

**SQI Diagnostics Inc.**  
**Condensed Interim Consolidated Statements of Financial Position**  
**(Unaudited)**  
(Amounts are in thousands of Canadian dollars)

	As at June 30, 2021	As at September 30, 2020
<b>Assets</b>		
<b>Current</b>		
Cash	\$5,008	\$2,596
Accounts receivable	231	477
Prepays and other assets	533	231
Inventory	622	364
	<b>6,394</b>	<b>3,668</b>
<b>Non-current</b>		
Right-of-use assets (Note 6)	2,464	2,838
Property and equipment (Note 4)	1,425	1,180
Intangible assets (Note 5)	421	384
	<b>4,310</b>	<b>4,402</b>
<b>Total Assets</b>	<b>\$10,704</b>	<b>\$8,070</b>
<b>Liabilities</b>		
<b>Current</b>		
Accounts payable and accrued liabilities	1,759	\$1,041
Contract liabilities	303	196
Lease obligations (Note 6)	240	228
	<b>2,302</b>	<b>1,465</b>
<b>Non-current</b>		
Lease obligation – long-term (Note 6)	2,442	2,731
Secured debentures (Note 7)	2,189	2,148
	<b>4,631</b>	<b>4,879</b>
<b>Total Liabilities</b>	<b>6,933</b>	<b>6,344</b>
<b>Shareholders' Equity</b>		
Capital stock (Note 8)	85,873	71,870
Warrants (Note 9)	5,602	10,371
Contributed surplus	23,656	22,900
Accumulated Other Comprehensive Income (Loss)	12	-
Deficit	(111,372)	(103,415)
	<b>3,771</b>	<b>1,726</b>
<b>Total Liabilities and Shareholder's Equity</b>	<b>\$10,704</b>	<b>\$8,070</b>

*Basis of Presentation and Going concern (Note 2)*

Approved by the Board

"Clive Beddoe"  
Director (Signed)

"Andrew Morris"  
Director (Signed)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**SQI Diagnostics Inc.**  
**Condensed Interim Consolidated Statements of Loss and Comprehensive Loss**  
**(Unaudited)**  
(Amounts are in thousands of Canadian dollars except per share amounts)

	Three Months Ended		Nine Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
<b>Revenue</b>				
Services revenue	\$158	\$30	\$382	\$244
Product sales	138	266	392	528
	<b>296</b>	296	<b>774</b>	772
<b>Expenses</b>				
Cost of products sold	44	107	127	165
Corporate and general (Note 12)	(1,467)	569	1,609	1,471
Sales and marketing (Note 13)	219	167	610	838
Research and development (Note 14)	2,026	787	5,993	3,507
Interest and accretion expense (Note 7)	132	139	392	547
	<b>954</b>	1,769	<b>8,731</b>	6,528
<b>Net loss</b>	<b>\$(658)</b>	\$(1,473)	<b>\$(7,957)</b>	\$(5,756)
Other Comprehensive Loss:				
Currency Translation Adjustment	(1)	-	12	-
<b>Net loss and comprehensive loss</b>	<b>\$(659)</b>	<b>\$(1,473)</b>	<b>\$(7,945)</b>	<b>\$(5,756)</b>
<b>Loss per share</b>				
Basic and diluted	<b>\$(0.00)</b>	\$(0.01)	<b>\$(0.02)</b>	\$(0.02)
<b>Weighted average number of common shares outstanding (thousands of shares)</b>	<b>346,521</b>	277,149	<b>330,340</b>	253,688

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**SQI Diagnostics Inc.**  
**Condensed Interim Consolidated Statements of Changes in Equity**  
**(Unaudited)**  
(Amounts are in thousands of Canadian dollars)

	Issued Capital Stock		Warrants	Contributed Surplus	Deficit	Accumulated Other Comprehensive Income (Loss)	Total Equity
	Number of Shares (thousands of shares)	Amount					
Balance as at September 30, 2019	231,341	\$64,729	\$11,827	\$19,817	(\$94,844)	\$-	\$1,529
Issued in connection with private placement (Note 8b,c)	45,444	4,100	-	-	-	-	4,100
Allocated to warrants – private placement (Note 8b,c)	-	(1,795)	1,795	-	-	-	-
Share issuance costs (Note 8b,c)	-	(36)	(21)	-	-	-	(57)
Warrants issued (Note 8 b,c)	-	-	345	-	-	-	345
Warrants exercised (Note 8 b,c)	29,011	3,381	(270)	-	-	-	3,111
Warrants expired (Note 9)	-	-	(978)	978	-	-	-
Options exercised (Note 10)	195	54	-	(24)	-	-	30
Stock-based compensation (Note 11)	-	-	-	305	-	-	305
Net loss and comprehensive loss	-	-	-	-	(5,756)	-	(5,756)
Balance as at June 30, 2020	305,991	\$70,433	\$12,698	\$21,076	\$(100,600)	\$-	\$3,607
<b>Balance as at September 30, 2020</b>	<b>308,095</b>	<b>\$71,870</b>	<b>\$10,371</b>	<b>\$22,900</b>	<b>\$(103,415)</b>	<b>\$-</b>	<b>\$1,726</b>
Warrants exercised (Notes 8d,e,f,g,h)	52,912	13,959	(3,498)	-	-	-	10,461
Options exercised (Note 10)	1,523	782	-	(329)	-	-	453
Warrants expired (Note 9)	-	-	(1,271)	1,271	-	-	-
Share issuance costs (Notes 8d,e,f,g,h)	-	(738)	-	-	-	-	(738)
Stock-based compensation (Note 11)	-	-	-	(186)	-	-	(186)
Currency translation adjustment	-	-	-	-	-	12	12
Net loss	-	-	-	-	(7,957)	-	(7,957)
Balance as at June 30, 2021	362,530	\$85,873	\$5,602	\$23,656	\$(111,372)	\$12	\$3,771

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

**SQI Diagnostics Inc.**  
**Condensed Interim Consolidated Statements of Cash Flows**  
**(Unaudited)**  
(Amounts are in thousands of Canadian dollars)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>June 30, 2021</b>	June 30, 2020	<b>June 30, 2021</b>	June 30, 2020
<b>Cash flows used in operating activities</b>				
Net loss	<b>\$(658)</b>	\$(1,473)	<b>\$(7,957)</b>	\$(5,756)
Add items not affecting cash				
Amortization – Intangible assets	<b>32</b>	31	<b>93</b>	93
- Property and equipment	<b>72</b>	75	<b>208</b>	221
- Right of use assets	<b>86</b>	91	<b>265</b>	288
Stock-based compensation	<b>(2,084)</b>	70	<b>(186)</b>	305
Accretion on debenture	<b>14</b>	12	<b>41</b>	148
Write down of inventory	-	95	-	95
Bad debts written off	-	-	-	26
	<b>(2,538)</b>	(1,099)	<b>(7,536)</b>	(4,580)
Changes in non-cash working capital items				
Accounts receivable, prepaids and other assets	<b>(2)</b>	(274)	<b>(56)</b>	(390)
Inventory	<b>(335)</b>	96	<b>(313)</b>	114
Accounts payable and accrued liabilities	<b>434</b>	(130)	<b>718</b>	(127)
Contract liabilities	<b>(119)</b>	149	<b>(91)</b>	32
	<b>(2,560)</b>	(1,258)	<b>(7,278)</b>	(4,951)
<b>Cash flows used in investing activities</b>				
Additions to Property and equipment	<b>(58)</b>	(35)	<b>(199)</b>	(113)
Additions to Intangible assets	<b>(28)</b>	(19)	<b>(131)</b>	(24)
Additions to Right of Use assets	-	(1)	-	(1)
	<b>(86)</b>	(55)	<b>(330)</b>	(138)
<b>Cash flows from financing activities</b>				
Proceeds from issuance of shares, net of issuance costs	<b>3,929</b>	3,133	<b>10,176</b>	7,185
Repayment of debenture				(1,000)
Lease payments	<b>(58)</b>	(51)	<b>(168)</b>	(220)
	<b>3,871</b>	3,082	<b>10,008</b>	5,965
Net change in cash during the period	<b>1,225</b>	1,769	<b>2,400</b>	876
Currency translation adjustment	<b>(1)</b>	-	<b>12</b>	-
Cash at beginning of period	<b>3,784</b>	2,551	<b>2,596</b>	3,444
<b>Cash at end of period</b>	<b>\$5,008</b>	\$4,320	<b>\$5,008</b>	\$4,320
<b>Cash Interest Paid</b>	<b>54</b>	67	<b>169</b>	294
<b>Non-Cash investing activities:</b>				
Acquisition of lab equipment through non-monetary exchange of goods/services	<b>198</b>	-	<b>198</b>	-

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

# **SQI Diagnostics Inc.**

## **Notes to Condensed Interim Consolidated Financial Statements**

**(Unaudited)**

**June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

---

### **1. NATURE OF OPERATIONS**

SQI Diagnostics Inc., (the "Company"), is incorporated under the *Canada Business Corporations Act*, is listed on the TSX Venture Exchange under the symbol SQD and trades on the OTCQB under the symbol SQIDF. The Company's head office and development center is located at 36 Meteor Drive, Toronto, Ontario. The Company is a life sciences company that develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics. The Company's goal is to become a leader in the development and commercialization of multiplexed blood tests to enable simultaneous measurement of important molecules like proteins, antibodies, and inflammatory biomarkers.

The Company is now expanding its business model into the rapid diagnostic testing market. Initially, we will be focusing on three business units targeting organ transplant, autoimmune disease, and serological testing. Under serological testing, we have an immediate priority to commercialize our developmental direct-to-consumer COVID-19 At-Home Antibody Test Kit and the RALI-Dx™ and RALI-fast™ Point-of-Care (POC) tests, to triage COVID-19 patients for respiratory distress.

### **2. BASIS OF PRESENTATION**

#### **Statement of Compliance**

These interim condensed consolidated financial statements are prepared in accordance with International Accounting Standard ("IAS") 34 - Interim Financial Reporting. Accordingly, certain information and disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), have been omitted or condensed. These interim condensed consolidated financial statements and the notes thereto should be read in conjunction with the audited consolidated financial statements of the Company for the year ended September 30, 2020.

These condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on August 17, 2021.

#### **Basis of Presentation and Going concern**

The consolidated financial statements have been prepared using the historical cost basis and have been prepared on a going concern basis that presumes the realization of assets and the discharge of liabilities in the normal course of business.

Since inception, the Company has focused on product research, development and more recently on commercialization activities. The Company has a history of net losses and negative cash flows from operations, which are expected to continue in the near term.

The Company's ability to continue as a going concern and execute on its research, development and commercialization activities is dependent upon the Company's ability to successfully generate product or service revenues, or to finance its cash requirements through further equity and/or debt financings.

Based on the foregoing, the Company will continue to pursue commercial sales, strategic partnering activities, and funding opportunities, however, no assurances can be given that it will be successful in generating revenues or raising additional investment capital to generate sufficient cash flows to continue as a going concern. As a result, these material uncertainties cast significant doubt regarding the Company's ability to continue as a going concern.

These condensed interim consolidated financial statements do not reflect the adjustments that might be necessary to the carrying amount of reported assets, liabilities, revenue, and expenses and the statement of financial position classification used if the Company was unable to continue operations in accordance with this assumption. Such adjustments could be material.

## **SQI Diagnostics Inc.**

### **Notes to Condensed Interim Consolidated Financial Statements**

**(Unaudited)**

**June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

---

## **2. BASIS OF PRESENTATION (continued)**

### **Basis of Consolidation**

The interim consolidated financial statements are expressed in Canadian dollars with all amounts being reported in thousands of dollars except for per share data.

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, SQI Diagnostics Systems Inc. & SQI US Inc. The Company's functional and presentation currency is Canadian dollars. The functional currencies of its two subsidiaries, SQI Diagnostics Systems Inc and SQI US Inc., are the Canadian and U.S. dollars, respectively.

Inter-company balances and transactions are eliminated upon consolidation.

## **3. CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS**

The preparation of the Company's interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and revenues and expenses at the end of the reporting period. However, uncertainty about these estimates, judgments and assumptions could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

Management reviews, on a regular basis, the Company's accounting policies, assumptions, estimates and judgments to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company's condensed interim consolidated financial statements, were the same as those found in note 3 to the Company's annual consolidated financial statements as of September 30, 2020 and 2019 and for the years ended September 30, 2020 and 2019.

**SQI Diagnostics Inc.**

**Notes to Condensed Interim Consolidated Financial Statements  
(Unaudited)**

**June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

**4. PROPERTY AND EQUIPMENT**

<b>Cost</b>	<b>Computer Hardware</b>	<b>Computer Software</b>	<b>Laboratory Fixtures and Equipment</b>	<b>Office Equipment</b>	<b>Leasehold Improvements</b>	<b>Total</b>
September 30, 2019	\$459	\$267	\$5,529	\$183	\$265	\$6,703
Additions	41	6	51	5	49	152
Transfers from inventory	-	-	100	-	-	100
Transfers to ROU Assets	(65)	-	-	-	-	(65)
September 30, 2020	\$435	\$273	\$5,680	\$188	\$314	\$6,890
<b>Additions</b>	<b>43</b>	<b>12</b>	<b>338</b>	<b>1</b>	<b>4</b>	<b>398</b>
<b>Transfers from inventory</b>	<b>-</b>	<b>-</b>	<b>55</b>	<b>-</b>	<b>-</b>	<b>55</b>
<b>Dispositions</b>	<b>-</b>	<b>-</b>	<b>(162)</b>	<b>-</b>	<b>-</b>	<b>(162)</b>
<b>June 30, 2021</b>	<b>\$478</b>	<b>\$285</b>	<b>\$5,911</b>	<b>\$189</b>	<b>\$318</b>	<b>\$7,181</b>

<b>Accumulated Amortization</b>	<b>Computer Hardware</b>	<b>Computer Software</b>	<b>Laboratory Fixtures and Equipment</b>	<b>Office Equipment</b>	<b>Leasehold Improvements</b>	<b>Total</b>
September 30, 2019	\$382	\$235	\$4,349	\$177	\$263	\$5,406
Amortization expense	21	19	254	2	3	299
Transfers to ROU Assets	(15)	-	20	-	-	5
September 30, 2020	\$388	\$254	\$4,623	\$179	\$266	\$5,710
<b>Amortization expense</b>	<b>23</b>	<b>16</b>	<b>163</b>	<b>1</b>	<b>4</b>	<b>208</b>
<b>Dispositions</b>	<b>-</b>	<b>-</b>	<b>(162)</b>	<b>-</b>	<b>-</b>	<b>(162)</b>
<b>June 30, 2021</b>	<b>\$411</b>	<b>\$270</b>	<b>\$4,624</b>	<b>\$180</b>	<b>\$270</b>	<b>\$5,756</b>

<b>Net Book Value</b>						
September 30, 2020	\$47	\$19	\$1,057	\$9	\$48	\$1,180
<b>June 30, 2021</b>	<b>\$66</b>	<b>\$15</b>	<b>\$1,287</b>	<b>\$9</b>	<b>\$48</b>	<b>\$1,425</b>



**SQI Diagnostics Inc.****Notes to Condensed Interim Consolidated Financial Statements****(Unaudited)****June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

**5. Intangible Assets**

Intangible Assets include Patents &amp; Trademarks and costs incurred in developing the Company's website.

<b>Cost</b>	
September 30, 2019	\$2,212
Additions	30
Write off of patents	(9)
September 30, 2020	\$2,233
Additions	<b>130</b>
June 30, 2021	<b>\$2,363</b>
<b>Accumulated Amortization</b>	
September 30, 2019	\$1,731
Amortization expense	124
Write off of patents	(6)
September 30, 2020	\$1,849
<b>Amortization expense</b>	<b>93</b>
<b>June 30, 2021</b>	<b>\$1,942</b>
<b>Net Book Value</b>	
September 30, 2020	\$384
<b>June 30, 2021</b>	<b>\$421</b>

**6. RIGHT-OF-USE ASSETS AND LEASE OBLIGATIONS**

	<b>Right-of-use-assets</b>	<b>Lease obligations</b>
Balance as at September 30, 2020	\$2,838	\$2,959
Amortization	(265)	-
Lease modification	(109)	(109)
Interest expense	-	169
Lease payments	-	(337)
<b>Balance as at June 30, 2021</b>	<b>\$2,464</b>	<b>\$2,682</b>
Less: current portion of lease obligations		<b>(240)</b>
Long-term lease obligations		<b>\$2,442</b>

The Company's lease obligations come due, as at June 30, 2021, as follows:

Less than 1 year	\$240
1 - 3 years	815
4 - 5 years	790
More than 5 years	837
Total	<b>\$2,682</b>

## **SQI Diagnostics Inc.**

### **Notes to Condensed Interim Consolidated Financial Statements**

**(Unaudited)**

**June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

---

#### **7. SECURED DEBENTURES**

On January 30, 2015 and February 20, 2015, the Company issued secured debentures (the "Debentures") with a principal amount of \$1,950,000 and \$1,286,000, respectively. The Debentures bore interest at a rate of 10% and were redeemable 60 months from the date of issuance. The Debentures matured during fiscal 2020 with \$1,000,000 of the February tranche and \$100,000 of accrued interest related to this amount being repaid by the Company. The maturity dates of the remaining \$2,236,000 Debentures were extended for an additional five years in agreement with the holders of these financial instruments. In addition, \$223,600 of accrued interest was added to the principal amount of the existing debentures resulting in new principal amounts of \$2,145,000 and \$314,600 as of January 30, 2020 and February 20, 2020, respectively. Approximately 85% of the existing Debentures were originally subscribed to by individuals who subsequently became board members and are thus considered related parties. The Debentures are secured by a general security agreement over all the present and future assets of the Company including intangible assets. Additionally, a total of 3,559,600 warrants originally issued in connection with the secured debentures expired unexercised upon maturity. The Company issued an aggregate of 4,739,139 new common share purchase warrants in connection with the amended Debentures. The warrants issued in connection with the January and February tranches are exercisable at prices of \$0.09 and \$0.085, respectively. Each common share purchase warrant entitles the holder thereof to acquire one common share of the Company for a period of 60 months from the date of issuance.

From time to time, the Company pursues amendments to its credit agreements based on prevailing market conditions. Such amendments, when completed, are considered by the Company to be debt modifications or extinguishments. The accounting treatment of a debt modification depends on whether the modified terms are substantially different than the previous terms. Terms of an amended debt agreement are considered to be substantially different based on qualitative factors, or when the discounted present value of the cash flows under the new terms discounted using the original effective interest rate, is at least ten percent different from the discounted present value of the remaining cash flows of the original debt. If the modification is not substantially different, it will be considered as a modification with any costs or fees incurred adjusting the carrying amount of the liability recorded through profit or loss at the date of modification. If the modification is substantially different, then the transaction is accounted for as an extinguishment of the old debt instrument with an adjustment to the carrying amount of the liability being recorded in the consolidated statements of operations immediately.

The Company determined that the amended terms of the Debentures constituted a substantial modification of the existing financial liability, and as result, the original debentures were extinguished with a new financial liability being recognized and a gain/loss recognized upon extinguishment.

The Debentures may be redeemed in whole or in part, at face value and without premium or penalty, at the option of the Company if at any time following the first anniversary of the date of issuance of the debentures, and prior to the maturity date of such debentures, the volume weighted average closing price of the Company's shares on the TSXV (or any other stock exchange on which such shares are then traded) is equal to or greater than \$1.00 per share for twenty (20) consecutive trading days.

The new Debentures were separated into their liability and equity components with the fair value of the liability calculated using a market rate of interest without warrants with the residual value allocated to the warrants. The amount allocated to the warrants was estimated at \$345,000.

## SQI Diagnostics Inc.

### Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

June 30, 2021 and 2020

(Amounts are in Canadian dollars; tabular amounts in thousands)

---

#### 7. SECURED DEBENTURES (continued)

The carrying value of the Debentures are accreted to their face value of \$2,459,600 using an effective interest rate of 13.9%.

	June 30, 2021	September 30, 2020
Secured debentures	\$2,460	\$2,460
Equity component of secured debenture	(345)	(345)
	2,115	2,115
Accretion in carrying amount of notes	74	33
Balance end of period	\$2,189	\$2,148

#### 8. CAPITAL STOCK

- (a) The Company has authorized an unlimited number of common shares.
- (b) On October 22, 2019, the Company closed the second tranche of a non-brokered private placement of an aggregate 1,000,000 units of the Company at \$0.10 per unit for gross proceeds of \$100,000. Each unit comprises one common share of the Company and one common share purchase warrant. Each warrant is exercisable at a price of \$0.13 and entitles the holder thereof to acquire one common share for a period of five years from the date of issuance. The proceeds from the issuance of units were allocated between capital stock and warrant capital based on their relative fair values, with \$45,000 being allocated to warrant capital. The fair value of the warrants was estimated using the Black-Scholes pricing model with the following assumptions: share price \$0.10; dividend yield 0%; risk free interest 1.53%; volatility 122%; and an expected life of 5 years. Expected volatility is based on historical volatility. The total share issuance costs were \$2,700 and \$1,200 was allocated to warrant capital.
- (c) On February 14 and March 5, 2020, the Company completed a non-brokered private placement of an aggregate of 44,444,444 units of the Company at \$0.09 per unit for gross proceeds of \$4,000,000. Each unit comprises one common share of the Company and one common share purchase warrant. Each warrant is exercisable at a price of \$0.12 and entitles the holder thereof to acquire one common share for a period of five years from the date of issuance, subject to accelerated expiry in certain circumstances. The proceeds from the issuance of units are allocated between capital stock and warrant capital based on their relative fair values, with \$1,750,000 being allocated to warrant capital. The fair value of the warrants was estimated using the Black-Scholes pricing model with the following assumptions for each of the respective tranches: share prices of \$0.08 and \$0.075; dividend yield 0%; risk free interest rates of 1.41% and 0.75%; volatility 118%; and an expected life of 5 years. Expected volatility is based on historical volatility. The total share issuance costs were \$46,000 and \$20,000 was allocated to warrant capital.
- (d) During the first quarter of fiscal 2021, a total of 2,248,260 common share purchase warrants were exercised for total gross proceeds of \$457,000. Of this total, 750,000 of the warrants, issued in connection with a March 2017 private placement, were exercised at a price of \$0.20 while 1,498,260 warrants issued in connection with a December 2017 private placement, were exercised at a price of \$0.21. The original value of the warrants was calculated using the Black-Scholes option pricing model. Accordingly, \$161,000 was deducted from the Warrant Capital account and transferred to Share Capital upon exercise. Total share issuance costs were approximately \$46,000.

## SQI Diagnostics Inc.

### Notes to Condensed Interim Consolidated Financial Statements

(Unaudited)

June 30, 2021 and 2020

(Amounts are in Canadian dollars; tabular amounts in thousands)

#### 8. CAPITAL STOCK

- (e) On December 31, 2020, a total of 19,074,997 warrants were exercised by certain insiders of the Company for total gross proceeds of \$4,000,000. A total of 18,500,000 of the warrants issued in connection with a March 2017 private placement were exercised at a price \$0.21 per share while 574,997 warrants issued in connection with a December 2017 private placement were exercised at a price \$0.20 per share. The original value of the warrants was calculated using the Black-Scholes option pricing model. Accordingly, \$1,351,000 was deducted from the Warrant Capital account and transferred to Share Capital upon exercise. The total share issuance costs were approximately \$428,000.
- (f) During the second quarter of fiscal 2021, a total of 11,900,972 common share purchase warrants were exercised for total gross proceeds of approximately \$2,066,000. Of this total, 11,795,416 warrants were issued in connection with private placements conducted between March 2017 and July 2019, with exercise prices ranging from \$0.11-\$0.21. The remaining 105,556 warrants exercised were issued in connection with a debt refinancing in January 2020 with an exercise price of \$0.09. The original value of the warrants was calculated using the Black-Scholes option pricing model. Accordingly, \$687,000 was deducted from the Warrant Capital account and transferred to Share Capital upon exercise. Total share issuance costs were approximately \$212,000.
- (g) During the second quarter of fiscal 2021, a total of 1,522,743 stock options were exercised at prices of \$0.15 and \$0.30 for total gross proceeds of approximately \$453,000. The original value of the options was calculated using the Black-Scholes option pricing model. Accordingly, \$329,000 was deducted from the Contributed Surplus account and transferred to Share Capital upon exercise. Total share issuance costs were approximately \$45,000.
- (h) During the third quarter of fiscal 2021, a total of 19,687,504 common share purchase warrants were exercised by certain insiders who are control persons, for total gross proceeds of approximately \$3,938,000. Of the insider warrants exercised, 19,687,504 insider warrants were exercised at a price of \$0.20 per share. The original value of the options was calculated using the Black-Scholes option pricing model. Accordingly, \$1,298,000 was deducted from Contributed Surplus account and transferred to Share Capital upon exercise. Total share issuance costs were approximately \$6,000.

#### 9. WARRANTS

The Company had the following warrants outstanding at June 30, 2021:

Number of Warrants	Exercise Price	Maturity
1,388	\$0.21	March 10, 2022
26,018	\$0.20	December 20, 2022 – August 24, 2023
12,344	\$0.17	July 12, 2024
32,300	\$0.13	September 25 and October 22, 2024
622	\$0.085	February 20, 2025
44,444	\$0.12	February 14, 2025, and March 5, 2025
117,116		

On January 30, 2020 and February 20, 2020, 3,559,600 warrants issued in connection with secured debentures in January and February 2015 expired unexercised. Accordingly, \$978,000 was transferred from warrant capital to contributed surplus in the quarter.

During the first quarter of fiscal 2021, a total of 7,630,945 warrants issued in connection with a private placement in December of 2015 with an exercise price of \$0.52 expired unexercised. Accordingly, \$1,271,000 was transferred from warrant capital to contributed surplus in the quarter.

**SQI Diagnostics Inc.****Notes to Condensed Interim Consolidated Financial Statements****(Unaudited)****June 30, 2021 and 2020**

(Amounts are in Canadian dollars; tabular amounts in thousands)

**10. STOCK OPTIONS**

The Company maintains a Stock Option Plan (the "Plan") for the benefit of employees, officers and directors. All options granted to individual optionees generally vest in three equal installments over a period of 12 to 36 months. The maximum number of common shares reserved for issuance under the Plan, together with any other employee stock option plans, options for services and employee share purchase plans, will not exceed 50,814,253. Options granted pursuant to the Plan are granted at an option price which will not be less than the fair market price at the time the options are granted.

The following summarizes the stock option activities under the Plan:

	<b>Nine Months Ended</b>			
	<b>June 30, 2021</b>		<b>June 30, 2020</b>	
	<b>Number of Options</b>	<b>Weighted Average Exercise Price</b>	<b>Number of Options</b>	<b>Weighted Average Exercise Price</b>
Beginning Balance	<b>42,400</b>	<b>\$ 0.20</b>	11,767	\$ 0.20
Granted	<b>2,410</b>	<b>\$0.22</b>	1,373	\$ 0.08
Exercised	<b>(1,523)</b>	<b>\$ 0.30</b>	(195)	\$0.15
Cancelled/Expired	<b>(474)</b>	<b>\$ 0.23</b>	(723)	\$0.27
Forfeited	<b>(30,123)</b>	<b>\$ 0.20</b>	(700)	\$ 0.17
Ending Balance	<b>12,690</b>	<b>\$ 0.19</b>	11,522	\$ 0.19
Exercisable	<b>7,871</b>	<b>\$ 0.17</b>	8,428	\$ 0.20

The Company had the following stock options outstanding under the Plan at June 30, 2021:

<b>Number of Options</b>	<b>Range of Exercise Prices</b>	<b>Weighted average time to maturity</b>
1,373	\$ 0.07 - 0.14	3.66 years
9,738	\$ 0.15 - 0.22	2.73 years
1,579	\$ 0.23 - 0.30	9.06 years
<b>12,690</b>		

## SQI Diagnostics Inc.

### Notes to Condensed Interim Consolidated Financial Statements (Unaudited)

June 30, 2021 and 2020

(Amounts are in Canadian dollars; tabular amounts in thousands)

#### 11. STOCK-BASED COMPENSATION

The total compensation expense recorded to contributed surplus for the nine months ended June 30, 2021 was \$(186,000), (nine-months ending June 30, 2020 - \$305,000). The net credit expense is attributable to the forfeiture of the CEO's stock options upon his departure from the Company.

The fair value of each option granted has been estimated at the date of grant or the date when it became measurable using the Black-Scholes option pricing model with the following weighted average inputs and assumptions at the measurement date:

	Nine Months Ended	
	June 30, 2021	June 30, 2020
Dividend Yield	0%	0%
Expected Volatility (historical data basis)	127%	123%
Risk-free Interest Rate	0.74%	0.58%
Share price and exercise price	\$0.22	\$0.08
Expected Life (years)	5.00	5.00
Weighted average grant date fair value	\$0.18	\$0.07

The Company estimates forfeiture rates based on historical experience with any change in estimate thereof reflected in the year they occur. The Company assumes a forfeiture rate of 10% to 40% based on the vesting period of the option and historical forfeiture rates.

#### 12. CORPORATE AND GENERAL EXPENSE

	Three Months Ended		Nine Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Salaries and wages	\$824	\$143	\$1,370	\$373
Subsidies	(23)	(26)	(57)	(26)
General and administrative	(289)	208	(108)	391
Professional and consulting	187	198	821	592
Stock-based compensation	(2,166)	46	(417)	141
Total Corporate and general expense by nature	\$(1,467)	\$569	\$1,609	\$1,471

The combination of the forfeiture of the CEO's stock options \$(2,473,000) and recovery of an outstanding customer balance \$(407,000) against which a reserve had already been taken previously, resulted in a net credit balance for Corporate & General expense.

## SQI Diagnostics Inc.

### Notes to Condensed Interim Consolidated Financial Statements (Unaudited)

June 30, 2021 and 2020

(Amounts are in Canadian dollars; tabular amounts in thousands)

#### 13. SALES AND MARKETING EXPENSE

	Three Months Ended		Nine Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Contractor fees	\$214	\$157	\$591	\$710
Travel and marketing	2	4	11	95
Stock-based compensation	3	6	8	33
Total Sales and marketing expense by nature	\$219	\$167	\$610	\$838

#### 14. RESEARCH AND DEVELOPMENT COSTS

	Three Months Ended		Nine Months Ended	
	June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Salaries and wages	\$1,232	\$705	\$2,964	\$2,392
Subsidies (CEWS & Biotalent)	(261)	(325)	(702)	(359)
Laboratory costs and supplies	775	332	2,933	881
Investment tax credit recoverable	-	(140)	-	(140)
Professional fees	10	-	10	-
Amortization – intangible assets (note 6)	32	31	93	93
Amortization – property and equipment (note 5)	73	75	207	221
Amortization – right of use assets (note 7)	86	91	265	288
Stock-based compensation	79	18	223	131
Total Research and development expense by nature	\$2,026	\$787	\$5,993	\$3,507

#### 15. CAPITAL RISK MANAGEMENT

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern so that it can complete its lead assay commercialization efforts and receive the required regulatory approvals to sell and market its products and provide returns for shareholders and benefits for other stakeholders.

The capital structure of the Company consists of shareholders' equity and secured debentures. The Company is not subject to externally imposed capital requirements.

#### 16. FINANCIAL RISK MANAGEMENT

##### (a) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash and accounts receivable are exposed to credit risk. The maximum credit risk exposure is the carrying amount. The credit risk on cash is mitigated because the counterparties are Schedule 1 Canadian banks. The credit risk on accounts receivable is due to the concentration of accounts as a result of the few large customers

**SQI Diagnostics Inc.**  
**Notes to Condensed Interim Consolidated Financial Statements**  
**(Unaudited)**  
**June 30, 2021 and 2020**  
(Amounts are in Canadian dollars; tabular amounts in thousands)

---

that comprise the Company's international customer base. The Company is also exposed to counterparty risk on accounts receivable. Credit risk on accounts receivable is managed by ongoing review of the amount and aging of accounts receivable.

Allowance for doubtful accounts and past due receivables are reviewed by Management at each balance sheet date. The Company updates its estimate of the allowance for doubtful accounts based on the evaluation of the recoverability of receivable balances from each customer taking into account historic collection trends of past due accounts. Receivables are written off once determined not to be collectible.

**(b) Interest Rate Risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its fixed and variable interest rate financial instruments. Fixed-rate instruments subject the Company to a fair value risk while the variable-rate instruments subject it to a risk of changes in cash flow. The Company's cash is exposed to cash flow interest rate risk as the Company invests cash at floating rates of interest in highly liquid instruments. Fluctuations in interest rates would not significantly impact interest income due to the short-term nature of the Company's investments. The Company's Debentures are subject to a fixed interest rate of 10%.

**(c) Currency Risk**

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is exposed to a higher currency risk due to its expanded US operations; however, this risk does not present a material concern for the Company at this time.

**(d) Fair Value Risk**

The carrying amount of accounts receivables and accounts payable and accrued liabilities, lease obligations and secured debentures approximate their fair values.

**(e) Liquidity Risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. At June 30, 2021, the Company had a working capital surplus of \$4,092,000 (September 30, 2020 - working capital surplus of \$2,203,000). The Company's liabilities consist of accounts payable, accrued liabilities, contract liabilities, lease obligations and the principal portion of debentures which require annual interest payments of \$245,960 on the anniversary date and the principal amount of \$2,459,600 which is due five years from the date of issuance. The Company has sufficient liquidity to meet its current obligations as they come due. The continuation of the Company's research, development and commercialization activities is dependent upon the Company's ability to generate product or service revenues or to finance its operations through further equity and or debt financings.